Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
SUMMARY
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) – Prolyl 4 hydroxylases (P4H) are iron%li%and 2-oxoglutamate-dependent dioxygenase enzymes and hypoxia-inducible transcription factor (HIF)-P4Hs play a critical role in the regulating oxygen homeostasis in the local tissues as well in the systemic circulation. This enzyme plays an important role in number of diseases including myocardial infarction, congestive heart failure, stroke, neurodegeneration, inflammatory disease, respiratory diseases, retinopathy and others.
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) pipeline Target constitutes close to 4 molecules. Out of which approximately 4 molecules are developed by Companies.The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn and Phase I stages are 2, 1 and 1 respectively. Report covers products from therapy areas Hematological Disorders and Toxicology which include indications Anemia in Chronic Kidney Disease (Renal Anemia), Anemia and Chemotherapy Induced Anemia.
The latest report Transmembrane Prolyl 4 Hydroxylase – Drugs In Development, 2022, outlays comprehensive information on the Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) – Prolyl 4 hydroxylases (P4H) are iron%li%and 2-oxoglutamate-dependent dioxygenase enzymes and hypoxia-inducible transcription factor (HIF)-P4Hs play a critical role in the regulating oxygen homeostasis in the local tissues as well in the systemic circulation. This enzyme plays an important role in number of diseases including myocardial infarction, congestive heart failure, stroke, neurodegeneration, inflammatory disease, respiratory diseases, retinopathy and others.
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) pipeline Target constitutes close to 4 molecules. Out of which approximately 4 molecules are developed by Companies.The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn and Phase I stages are 2, 1 and 1 respectively. Report covers products from therapy areas Hematological Disorders and Toxicology which include indications Anemia in Chronic Kidney Disease (Renal Anemia), Anemia and Chemotherapy Induced Anemia.
The latest report Transmembrane Prolyl 4 Hydroxylase – Drugs In Development, 2022, outlays comprehensive information on the Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.)
- The report reviews Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics and enlists all their major and minor projects
- The report assesses Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) – Overview
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) – Companies Involved in Therapeutics Development
FibroGen Inc
GSK plc
Japan Tobacco Inc
Jiangsu Hengrui Medicine Co Ltd
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) – Drug Profiles
daprodustat – Drug Profile
Product Description
Mechanism Of Action
History of Events
DDO-3055 – Drug Profile
Product Description
Mechanism Of Action
History of Events
enarodustat – Drug Profile
Product Description
Mechanism Of Action
History of Events
molidustat – Drug Profile
Product Description
Mechanism Of Action
History of Events
roxadustat – Drug Profile
Product Description
Mechanism Of Action
History of Events
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) – Dormant Products
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) – Discontinued Products
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) – Product Development Milestones
Featured News & Press Releases
Jun 06, 2022: A roxadustat resurrection: Astellas pull ahead with updated safety data
May 19, 2022: Astellas analysis shows no evidence of increased risk of cardiovascular events or mortality with Roxadustat compared with erythropoiesis-stimulating agents (ESAs) at 59th ERA Congress 2022
May 16, 2022: Astellas to present new research further supporting Roxadustat safety in the treatment of symptomatic anemia of chronic kidney disease at 59th ERA Congress 2022
Apr 25, 2022: Spherix uncovers key differences in the management of chronic kidney disease patients in Europe versus the U.S.
Apr 19, 2022: US Food and Drug Administration accepts New Drug Application for daprodustat
Mar 01, 2022: European Medicines Agency (EMA) accepts marketing authorisation application for daprodustat
Jan 04, 2022: Shenzhen Xinlitai Pharmaceutical announces acceptance of the listing application of Ennarestat Tablets
Nov 05, 2021: GSK announces positive Phase III efficacy and safety data for daprodustat in patients with anaemia due to chronic kidney disease
Oct 25, 2021: FibroGen announces analyses from roxadustat global phase 3 program at American Society of Nephrology Kidney Week 2021
Oct 18, 2021: GSK to present update on Daprodustat at the American Society of Nephrology Kidney Week 2021
Aug 25, 2021: FibroGen announces positive topline results from phase 2 clinical trial of roxadustat for the treatment of chemotherapy induced anemia
Aug 20, 2021: Astellas receives European Commission approval for first-in-class EVRENZO (roxadustat) for adult patients with symptomatic anemia of chronic kidney disease
Aug 12, 2021: FDA declines to approve FibroGen’s roxadustat for anaemia of CKD
Aug 06, 2021: Trials reveal efficacy and safety of oral drug for treating anemia associated with kidney disease
Jul 19, 2021: GSK’s daprodustat shows positive data for anaemia in Phase III ASCEND trials
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) – Overview
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) – Companies Involved in Therapeutics Development
FibroGen Inc
GSK plc
Japan Tobacco Inc
Jiangsu Hengrui Medicine Co Ltd
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) – Drug Profiles
daprodustat – Drug Profile
Product Description
Mechanism Of Action
History of Events
DDO-3055 – Drug Profile
Product Description
Mechanism Of Action
History of Events
enarodustat – Drug Profile
Product Description
Mechanism Of Action
History of Events
molidustat – Drug Profile
Product Description
Mechanism Of Action
History of Events
roxadustat – Drug Profile
Product Description
Mechanism Of Action
History of Events
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) – Dormant Products
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) – Discontinued Products
Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) – Product Development Milestones
Featured News & Press Releases
Jun 06, 2022: A roxadustat resurrection: Astellas pull ahead with updated safety data
May 19, 2022: Astellas analysis shows no evidence of increased risk of cardiovascular events or mortality with Roxadustat compared with erythropoiesis-stimulating agents (ESAs) at 59th ERA Congress 2022
May 16, 2022: Astellas to present new research further supporting Roxadustat safety in the treatment of symptomatic anemia of chronic kidney disease at 59th ERA Congress 2022
Apr 25, 2022: Spherix uncovers key differences in the management of chronic kidney disease patients in Europe versus the U.S.
Apr 19, 2022: US Food and Drug Administration accepts New Drug Application for daprodustat
Mar 01, 2022: European Medicines Agency (EMA) accepts marketing authorisation application for daprodustat
Jan 04, 2022: Shenzhen Xinlitai Pharmaceutical announces acceptance of the listing application of Ennarestat Tablets
Nov 05, 2021: GSK announces positive Phase III efficacy and safety data for daprodustat in patients with anaemia due to chronic kidney disease
Oct 25, 2021: FibroGen announces analyses from roxadustat global phase 3 program at American Society of Nephrology Kidney Week 2021
Oct 18, 2021: GSK to present update on Daprodustat at the American Society of Nephrology Kidney Week 2021
Aug 25, 2021: FibroGen announces positive topline results from phase 2 clinical trial of roxadustat for the treatment of chemotherapy induced anemia
Aug 20, 2021: Astellas receives European Commission approval for first-in-class EVRENZO (roxadustat) for adult patients with symptomatic anemia of chronic kidney disease
Aug 12, 2021: FDA declines to approve FibroGen’s roxadustat for anaemia of CKD
Aug 06, 2021: Trials reveal efficacy and safety of oral drug for treating anemia associated with kidney disease
Jul 19, 2021: GSK’s daprodustat shows positive data for anaemia in Phase III ASCEND trials
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by FibroGen Inc, 2022
Pipeline by GSK plc, 2022
Pipeline by Japan Tobacco Inc, 2022
Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Discontinued Products, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by FibroGen Inc, 2022
Pipeline by GSK plc, 2022
Pipeline by Japan Tobacco Inc, 2022
Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Dormant Products, 2022 (Contd..2)
Discontinued Products, 2022
LIST OF FIGURES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
